Gossamer Bio, which is developing its seralutinib DPI for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Rainer Zimmermann as VP of Medical Affairs. Zimmermann was most recently Global Medical Leader, Pulmonary Hypertension, at Janssen. Prior to Johnson & Johnson, Zimmermann served as Global Medical Lead, PH Franchise, at Actelion.
Seralutinib for inhalation is the only pipeline candidate currently listed on the company’s web site. In December 2022, Gossamer announced that the Phase 2 TORREY trial of seralutinib in PAH patients had met its primary endpoint.
Gossamer Chairman and CEO Faheem Hasnain commented, “We are thrilled to have Rainer join us at such a critical juncture for the seralutinib program. The global Phase 3 PROSERA study is well underway with multiple active clinical sites, putting us on track to reach our goal of having more than 20 sites activated by year end to support our enrollment timeline. Rainer’s extensive experience in successfully developing and launching multiple PAH therapies as a global medical affairs leader will perfectly complement the strong development and commercial teams we have brought together at Gossamer.”
Zimmermann said, “Seralutinib represents an important new mechanism of action as an inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor targeting the underlying proliferative, inflammatory, and fibrotic pathways operative in PAH. I am excited to join the Gossamer team and look forward to contributing to our efforts to bring this promising therapy to patients with PAH.”
Read the Gossamer Bio press release.
